{
    "clinical_study": {
        "@rank": "51918", 
        "arm_group": [
            {
                "arm_group_label": "Kovacaine Mist", 
                "arm_group_type": "Experimental", 
                "description": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100\u00b5L; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100\u00b5L (200\u00b5L total); subjects weighting more than 40kg will receive 2 sprays of 200\u00b5L (400\u00b5L total);"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100\u00b5L; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100\u00b5L (200\u00b5L total); subjects weighting more than 40kg will receive 2 sprays of 200\u00b5L (400\u00b5L total);"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy of Kovacaine Mist, and Placebo for\n      inducing pulpal anesthesia of the maxillary teeth in pediatric patients."
        }, 
        "brief_title": "Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Anesthesia", 
        "detailed_description": {
            "textblock": "The study will employ a multi-center, randomized, double-blind, placebo-controlled,\n      parallel-groups design to demonstrate the safety and efficacy of Kovacaine Mist delivered\n      intranasally for inducing pulpal anesthesia of maxillary permanent teeth numbers 4 to 13\n      (maxillary right second premolar to maxillary left second premolar) or maxillary primary\n      teeth numbers A to J (maxillary right second primary molar to maxillary left second primary\n      molar) sufficient to allow completion of the Study Dental Procedure.  The maxillary teeth\n      will be categorized in two subsets, anterior teeth (permanent teeth numbers 6 to 11 and\n      primary teeth numbers C to H) and posterior teeth (permanent teeth numbers 4, 5, 12, 13 and\n      primary teeth numbers A, B, I, J).\n\n      The intent is to treat 90 male and female subjects aged 3 to 17 years, inclusive, at 3 study\n      sites, 2:1 randomization within each study site, and an overall goal of 60 subjects treated\n      with Kovacaine Mist and 30 treated with placebo.  Subjects will receive Kovacaine Mist or\n      placebo (2:1) according to the kit randomization plan within three dosing strata (100 \u00b5L,\n      200 \u00b5L or 400 \u00b5L) based on subject weight at entry: subjects weighing 10 to <20 kg, 20 to\n      <40 kg and \u2265 40 kg will be assigned to the 100 \u00b5L, 200 \u00b5L or 400 \u00b5L dose group,\n      respectively.  Recruitment will be from diverse pediatric dental patient populations.  To\n      ensure adequate representation in the 3 dose/weight groups, each stratum will contain at\n      least 25% of subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 3-17 years of age inclusive.\n\n          -  Need for an operative restorative dental procedure and requiring local anesthesia on\n             a single vital maxillary primary tooth (#A to J) or permanent tooth (#4 to13), with\n             no evidence of pulpal pathology.\n\n          -  Normal lip, nose, eyelid, and cheek sensation.\n\n          -  Accompanied and/or represented by a parent or guardian able to comprehend and sign\n             the informed consent document.\n\n          -  Subject able to understand and provide assent to an age-appropriate subject assent\n             form (as defined by local practice or regulation).\n\n          -  Patient or parent/guardian able to communicate with the investigator and comply with\n             the requirements of the protocol.\n\n          -  Patency of the naris on the same side as the tooth undergoing the Study Dental\n             Procedure (the Study Treatment Tooth).\n\n        Exclusion Criteria:\n\n          -  Having received dental care requiring a local anesthetic within the 24 hours\n             preceding study entry.\n\n          -  History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local\n             anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).\n\n          -  History of allergy or hypersensitivity to lidocaine, oxymetazoline, epinephrine, or\n             sulfite preservatives.\n\n          -  Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.\n\n          -  Nursing, pregnant, suspected of being pregnant, or trying to become pregnant.\n             (Females of child-bearing potential will be required to undergo urine testing on the\n             day of, but prior to, study drug administration to rule out pregnancy.)\n\n          -  Inadequately controlled thyroid disease of any type.\n\n          -  Having received any investigational drug (including Kovacaine Mist) and/or\n             participation in any clinical trial within 30 days of study participation.\n\n          -  Frequent nose bleeds (\u2265 5 per month).\n\n          -  History of congenital or idiopathic methemoglobinemia.\n\n          -  Presence of an upper respiratory infection and/or fever defined as body temperature\n             \u2265100.4\u00b0 (38\u00b0C) on the day of and prior to study drug administration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844830", 
            "org_study_id": "SR 3-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Kovacaine Mist", 
                "intervention_name": "Tetracaine HCl 3% and Oxymetazoline HCl 0.05%", 
                "intervention_type": "Drug", 
                "other_name": "Kovacaine Mist"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracaine", 
                "Oxymetazoline", 
                "Phenylephrine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "operative", 
            "dental procedure"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Loma Linda", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92350"
                    }, 
                    "name": "Center for Dental Research Loma Linda University School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Collins", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80525"
                    }, 
                    "name": "Big Grins"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Time of dental procedure: for subjects who receive the 100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window", 
            "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).", 
            "safety_issue": "No", 
            "time_frame": "100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time of dental procedure: for subjects who receive the 100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window", 
                "measure": "Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no) by dose (100 \u00b5L, 200 \u00b5L or 400 \u00b5L).", 
                "safety_issue": "No", 
                "time_frame": "100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window"
            }, 
            {
                "description": "Time of dental procedure: for subjects who receive the 100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window", 
                "measure": "Completion of the study dental procedure without need for rescue by injection of local anesthetic (yes/no) by age group (3-5, 6-11, and 12-17 years old, inclusive).", 
                "safety_issue": "No", 
                "time_frame": "100\u00b5L dose - at 10 minutes, +3 minute window; for subjects who receive the 200\u00b5L or 400\u00b5L dose - at 15 minutes, +3 minute window"
            }, 
            {
                "measure": "Incidence of adverse events (AEs) by dose and age group.", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline to 120 minutes following drug administration"
            }
        ], 
        "source": "St. Renatus, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Triligent International", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Tegra Analytics", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Renatus, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}